Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
WATCH: IDF strikes, dismantles missile launchers in southern Lebanon - 2What's Your Number one Superhuman Film Made?
- 3A mom's viral post is raising the question: Do kids need snacks? Dietitians have answers.
- 4Federal judge upholds Hawaii's new climate change tax on cruise passengers
- 5A throat bone settles it - Nanotyrannus was not a juvenile T. rex
- Turning into a Distributed Writer: My Composing Process
- Two Passover initiatives target isolation and safety for Israel’s elderly
- Investigating Inside Plan and Home Style: Change Your Residing Space
- Nations for Rock Climbing
- Vote In favor of Your Favored Web based Dating Application
- Artemis II live updates: NASA's moon mission breaks Apollo record for farthest distance humans have traveled from Earth
- Instructions to Keep an Inspirational perspective After Cellular breakdown in the lungs Treatment
- Vote in favor of the subject that you see as generally captivating and intelligent!
- Palestinians protest against Israel's new death penalty law
